IL320916A - Bladder cancer treatment with anti-PD-L1 antibody - Google Patents

Bladder cancer treatment with anti-PD-L1 antibody

Info

Publication number
IL320916A
IL320916A IL320916A IL32091625A IL320916A IL 320916 A IL320916 A IL 320916A IL 320916 A IL320916 A IL 320916A IL 32091625 A IL32091625 A IL 32091625A IL 320916 A IL320916 A IL 320916A
Authority
IL
Israel
Prior art keywords
durvalumab
patients
bladder cancer
treatment
subject
Prior art date
Application number
IL320916A
Other languages
English (en)
Hebrew (he)
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of IL320916A publication Critical patent/IL320916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL320916A 2017-02-16 2018-02-16 Bladder cancer treatment with anti-PD-L1 antibody IL320916A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer

Publications (1)

Publication Number Publication Date
IL320916A true IL320916A (en) 2025-07-01

Family

ID=63169615

Family Applications (3)

Application Number Title Priority Date Filing Date
IL320916A IL320916A (en) 2017-02-16 2018-02-16 Bladder cancer treatment with anti-PD-L1 antibody
IL302777A IL302777A (en) 2017-02-16 2018-02-16 Bladder cancer treatment with anti-PD-L1 antibody
IL268460A IL268460A (en) 2017-02-16 2019-08-04 Treatment of bladder cancer with an antibody against pd-l1

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL302777A IL302777A (en) 2017-02-16 2018-02-16 Bladder cancer treatment with anti-PD-L1 antibody
IL268460A IL268460A (en) 2017-02-16 2019-08-04 Treatment of bladder cancer with an antibody against pd-l1

Country Status (12)

Country Link
US (2) US20190359715A1 (enExample)
EP (1) EP3582805A4 (enExample)
JP (2) JP2020507596A (enExample)
KR (3) KR20230145547A (enExample)
CN (2) CN118001389A (enExample)
AU (2) AU2018221822A1 (enExample)
CA (1) CA3052652A1 (enExample)
EA (1) EA201991870A1 (enExample)
IL (3) IL320916A (enExample)
MA (1) MA47509A (enExample)
SG (1) SG11201907211TA (enExample)
WO (1) WO2018152415A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023025321A2 (pt) * 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
WO2021234150A1 (en) * 2020-05-21 2021-11-25 Astrazeneca Ab Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
BR122023025321A2 (pt) * 2014-05-13 2024-02-20 Medimmune Limited Uso de anticorpos anti-b7-h1 e anti-ctla-4
BR112017018234A2 (pt) * 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
PL3303632T5 (pl) * 2015-05-29 2023-07-03 F. Hoffmann-La Roche Ag Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
EP3387155A4 (en) * 2015-12-10 2019-06-12 Definiens AG METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
EP3448428A4 (en) * 2016-04-25 2019-11-27 Medimmune, LLC COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료

Also Published As

Publication number Publication date
IL268460A (en) 2019-09-26
EP3582805A1 (en) 2019-12-25
SG11201907211TA (en) 2019-09-27
US20220332828A1 (en) 2022-10-20
CA3052652A1 (en) 2018-08-23
JP2020507596A (ja) 2020-03-12
EP3582805A4 (en) 2021-03-10
EA201991870A1 (ru) 2020-02-12
KR20230145547A (ko) 2023-10-17
CN110290803A (zh) 2019-09-27
KR20190117014A (ko) 2019-10-15
IL302777A (en) 2023-07-01
US20190359715A1 (en) 2019-11-28
JP2024038034A (ja) 2024-03-19
AU2025201227A1 (en) 2025-03-13
MA47509A (fr) 2019-12-25
CN118001389A (zh) 2024-05-10
KR20250025517A (ko) 2025-02-21
WO2018152415A1 (en) 2018-08-23
AU2018221822A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
JP7641704B2 (ja) リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用
US20180282417A1 (en) Tumor burden as measured by cell free dna
TW201839400A (zh) 用於癌症之診斷及治療方法
WO2016030455A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
US20170275347A1 (en) Methods for identifying patients responsive to anti-pd-l1 antibody therapy
US20250340645A1 (en) Methods of treating tumor
CN114174538A (zh) 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
WO2021160152A1 (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114728070A (zh) 用于癌症疗法的复合生物标记物
CN114174537A (zh) 细胞定位特征和组合疗法
WO2019164870A1 (en) Expression of signature mrnas for identifying patients responsive to anti-pd-l1 antibody therapy
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
CN118785922A (zh) 靶向dll3的癌症治疗